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Abstract
This manuscript investigates unconditional and conditional-on-stopping maxi-
mum likelihood estimators (MLEs), information measures and information loss as-
sociated with conditioning in group sequential designs (GSDs). The possibility of
early stopping brings truncation to the distributional form of MLEs; sequentially,
GSD decisions eliminate some events from the sample space. Multiple testing in-
duces mixtures on the adapted sample space. Distributions of MLEs are mixtures of
truncated distributions. Test statistics that are asymptotically normal without GSD,
have asymptotic distributions, under GSD, that are non-normal mixtures of truncated
normal distributions under local alternatives; under fixed alternatives, asymptotic dis-
tributions of test statistics are degenerate. Estimation of various statistical quantities
such as information, information fractions, and confidence intervals should account
for the effect of planned adaptations. Calculation of adapted information fractions
requires substantial computational effort. Therefore, a new GSD is proposed in which
stage-specific sample sizes are fully determined by desired operational characteristics,
and calculation of information fractions is not needed.
Keywords: Adaptive designs, maximum likelihood estimation, asymptotic distribution the-
ory, interim analyses, local alternative hypotheses.
1
ar
X
iv
:1
90
8.
01
41
1v
1 
 [s
tat
.M
E]
  4
 A
ug
 20
19
1 Introduction
Group sequential designs (GSDs) optimize resource allocation and benefit from the possibil-
ity of efficacy- and/or futility-driven early stopping. Along with these attractive properties,
a few challenges require attention from statisticians. Specifically, many group sequential
methods rely on the the joint canonical distribution assumption (Section 3.1, Jennison and
Turnbull (1999)) and/or Brownian motion theory [Section 2.1, Proschan et al. (2006)] to
justify the choice of a GSD. These assumptions state that stage-specific standardized test
statistics follow a multivariate normal distribution, or converge to multivariate normality
asymptotically. Multivariate normality, however, does not hold for cumulative standard-
ized tests statistics used in common GSD methods including Pocock, O’Brien & Fleming,
and Haybittle-Peto GSDs, not for finite sample sizes, and not asymptotically against local
alternatives. The popular SAS’s SEQDESIGN procedure, R’s gsDesign package, Cytel’s
EAST and others overcome this difficulty by using a recursive sub-density formula [Ar-
mitage et al. (1969)] for assessing type I and power properties. Nonetheless, the impact of
non-normality on other statistical quantities such as Fisher information, the information
fraction, and repeated confidence intervals, is not widely recognized.
Multivariate normality of many commonly used stage-specific test statistics (Z1, . . . , ZK),
and consequently their cumulative versions Z =
(
Z(1), . . . , Z(K)
)
, holds without sequential
adaptations. The use of an early stopping criterion, however, eliminates the possibility of
some realizations of Z. On its true adaptation-rule driven support, the distribution of Z
differs from normal. Thus, unadapted distributional assumptions should be considered to-
gether with the planned adaptation scheme to identify the adaptation-rule driven support
of Z and its distribution on this adapted support.
Many indications that joint normality does not hold after interim adaptations have been
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reported. Demets and Lan (1994) pointed out that the distribution of Z(k) is not normal
and should be estimated recursively. Jennison and Turnbull (1999) plotted the density
of a normal test statistic in GSD settings, where discontinuity points clearly showed non-
normality. Li et al. (2002) found the joint density of stage 1 and stage 2 standardized
test statistics not to be bivariate normal. Local asymptotic non-normality was established
following sample size recalculations (SSRs) that depend on an interim observed treatment
effect [Tarima and Flournoy (2019)]; and a GSD with a single interim analysis can be
viewed as a special case of an SSR. Maximum likelihood estimators (MLEs) converging to
random mixtures of normal variables have been found in other adaptive designs [Ivanova
et al. (2000), Ivanova and Flournoy (2001), May and Flournoy (2009), Lane and Flournoy
(2012)].
In studying estimation, several authors have investigated the effect of GSDs on the
sample space, bias, uncertainty measures and the amount of information; see Whitehead
(1986), Liu and Hall (1999), Liu et al. (2006), Brannath et al. (2006), Schou and Marschner
(2013), Milanzi et al. (2015), Graf et al. (2016), Shimura et al. (2017) and Marschner and
Schou (2018).
Whitehead (1986) investigated bias in GSDs and suggested a correction. Liu and Hall
(1999) and Liu et al. (2006) recognized change in support in the one-parameter exponential
family, and investigated unbiased estimation. The adaptation-driven change in support is
critical for derivation MLEs’ distributions in Section 2. Milanzi et al. (2015) developed
a likelihood approach that applies when the early stopping rule does not depend on the
parameter of interest. Schou and Marschner (2013) recognized presence of truncation in
the joint distribution of stage-specific test statistics. Brannath et al. (2006) and Graf et al.
(2016) investigated bias and MSEs in sample size modification problems. A comprehensive
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simulation study comparing various GSD estimators of a parameter of interest is reported in
Shimura et al. (2017). Marschner and Schou (2018) have found information in conditional
and unconditional GSD MLEs and quantified loss associated with conditioning. As it is
shown in Section 2, unconditional and conditional information measures differ from what
they reported in supplementary material to their manuscript, but the information loss is
the same.
However, the normality and asymptotic normality assumption continues to be directly
used with non-normally distributed statistics. Mehta et al. (2007) built repeated confidence
intervals. Koopmeiners et al. (2012) explored MLEs conditional on stopping but assumed
asymptotic normality to evaluate their uncertainty. Martens and Logan (2018) relied on
asymptotic normality for evaluating regression coefficients under the Fine–Gray model in
GSD settings. Asendorf et al. (2019) evaluated asymptotic properties with SSR under
a fixed alternative for negative binomial random variables. Gao et al. (2013) is a rare
exception in not making a normality assumption; these authors mostly dealt with set
operations and probabilities and, using stage-wise ordering of events, they calculated P-
values, confidence intervals, and a median unbiased estimate of the parameter of interest.
Asymptotic normality holds when a sequential study is powered against a fixed (not
local) alternative. The problem is that all consistent tests asymptotically reject the null
in favor of any fixed alternative hypothesis with 100% statistical power. As the sample
size increases, with a proportional increase of all stage-specific sample sizes, the probability
to reject the converges to 1 at stage 1 and tests statistics degenerate to a point mass, see
Section 7.4 in Fleming and Harrington (1991). Thus, for large samples at fixed alternatives,
the need for a power concept and the need for an interim analysis disappears.
To mitigate the limited applicability of multivariate normality to GSD trials with pos-
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sibility of early stopping, many researchers rely on a sequential recursive formula suggested
by Armitage et al. (1969) to find the distribution of Z(k) conditional on reaching stage k.
In this manuscript, Section 2 introduces notation for GSDs with stopping rules depen-
dent on a parameter of interest and shows through a few examples of two-stage GSDs that
conditional and unconditional distributions are truncated or mixtures of truncated distri-
butions. Fisher information in MLEs is also derived in this section. Section 3 presents a
method for designing a sequential experiment controlling a pre-determined power against
a sequence of ordered alternatives while controlling type 1 error. This new approach does
not use information fraction arguments and the design is fully driven by desired operational
characteristics. Section 4 derives a local asymptotic distribution of the MLEs, which is a
mixture of truncated normal distributions. Section 5 shows an illustrative application of
the theory. Finally, Section 6 concludes this article with a short summary.
2 Likelihood in Group Sequential Designs
Consider a random variable X with a p.d.f or a p.m.f. fX (x|θ) and the objective of testing
the null hypothesis H0 : θ = 0 with α-level type 1 error and 1− β power at an alternative
H1 : θ = θ1. In GSDs, it is convenient to group the random sample in vectors corresponding
interim analyses: X1, . . . ,XK , where Xk = (Xn(k−1)+1, . . . , Xn(k)); n(k) =
∑k
i=1 ni; ni is a
total number of observations in a stage i, 1 ≤ i ≤ k ≤ K, and n(0) = 0. Each stage
terminates with an analysis that results in a decision to stop the study or to enroll a new
group of patients. Every GSD stage is assumed to be “reachable”, that is, there is a positive
probability of reaching each stage. Further, to simplify the material, the term density is
used to refer to probability measures without formally distinguishing between p.m.f.s and
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p.d.f.s.
The assumption of a joint canonical distribution states that Z follows a multivariate
normal distribution with a vector of means
(
θ
√I1, . . . , θ
√IK
)
and a covariance matrix
with elements
√Ik1/Ik2 , 1 ≤ k1 ≤ k2 ≤ K [Section 3.1 in Jennison and Turnbull (1999)].
Normal approximations are useful for many statistical tests. For example, if a researcher is
interested in estimating θ with i.i.d. observations and the MLE of θ at the end of stage k is
θ̂k, then under common regularity conditions,
√
nk(θ̂k − θ)/σθ → N(0, 1) and the statistic
Zk =
√
nk θ̂k/σθ → N(0, 1) when θ = 0. Then if the sample size is large enough, a normal
approximation is reasonable. But when the Zk is combined with Z1, . . . , Zk−1 in a pooled
test statistic Z(k), the possibility of early stopping breaks the joint canonical assumption and
makes Z(k) non-normally distributed. This non-normality is illustrated with the example
of Pocock’s two-stage design in Section 2.3. Now a few finite sample results are presented;
asymptotic results are reported in Section 4.
2.1 Conditional and Unconditional Maximum Likelihood Esti-
mation
In GSDs, α-spending functions determine cutoff values {c1, . . . , cK} that drive decisions to
stop at stage k (for 1 ≤ k < K − 1) or continue through stage K. These decisions are
defined by the events
{∩k−1j=1 {Z(j) ≤ cj}}∩{Z(k) > ck} and ∩K−1j=1 {Z(j) ≤ ck}, respectively,
and they are conveniently summarized by a random variable denoting the stopping stage:
D := K · I (∩K−1j=1 {Z(j) ≤ cj})+ K−1∑
k=1
k · I ((∩k−1j=1 {Z(j) ≤ cj}) ∩ {Z(k) > ck})
defined on 1, . . . , K.
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The statistic Z(k) is a function of the observations X (k) = (X1, . . . , Xn(k)) that were
observed prior to stopping. D will appear as random index, such as in X(D), to underline
the fact that the stopping stage is unknown and is described probabilistically though the
random variable D. The fixed index k in X(k) indicates that the random variable D took
value k (the experiment stopped at stage k). Thus, X(k) is the random variable X(D)
conditioned on D = k. Given D = k, the values {xj : j ≥ n(k)} are unobserved and hence
do not contribute to the density; indeed, they do not belong to the adaptation-rule driven
sample space, and consequently, they do not belong to a σ-field defined on the experiment’s
sample space, measurable space, probability space, and hence, to the statistical experiment
as a whole. Some researchers view {xj : j ≥ n(k)} as missing data, but in this paper, by
analogy with structural zeroes in contingency tables, these values are excluded from the
sample space.
Now the joint density for this GSD can be written as
fX(D)
(
x (D)|θ
)
:=
K∏
k=1
[fX(k)(x (k)|θ)]I(D=k) =
K∏
k=1
f subX(k) , (1)
where f subX(k) := [fX(k)(x (k)|θ)]I(D=k) denotes sub-densities with support defined by D = k,
k = 1, . . . , K. The joint density (1) is a mixture with its components defined on non-
overlapping regions of the density’s support. Considering the density (1) conditional on
the observed data,
(
k,x (k)
)
, the (unconditional) likelihood is
L (θ|k,x (k)) = f subX(k) . (2)
In contrast, the density of observations conditional on stopping at stage k, i.e., the density
of X(k) = X(D)|{D = k}, is
f cX(k) := fX(D)
(
x (D)|D = k, θ
)
=
I (D = k)
Prθ (D = k)
fX(k)
(
x (k)|θ
)
= I (D = k)
f subX(k)
Prθ (D = k)
(3)
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with associated likelihood
Lc (θ|k,x (k)) = I (D = k) f subX(k)
Prθ (D = k)
. (4)
The indicator function in (3) and (4) emphasizes that support for the random variables
is reduced by the conditioning (see Figure 1). Note also in Figure 1 that the support
conditional on stopping at one stage is disjoint from the support conditional on stopping
at another stage. If the stopping rule is not random and the experiment stops with n(k)
observations, Prθ(D = k) ≡ 1 and
Lfix (θ|k,x (k)) = fX(k) . (5)
Both L and Lc are functions of θ and the observed data (k,x (k)), but L and Lc are
continuous functions only of θ and have discontinuities in (k,x (k)) since the distribution
of X(D) is a mixture. These discontinuities are inherited by unconditional and conditional
MLEs θ̂ and θ̂c, respectively, that are defined below. Adaptation can change distributions
of the MLEs and their information measures.
Conditional on D = k, MLEs maximizing L and Lc, respectively, are
θ̂(k) = arg max
θ
f subX(k) and θ̂
c
(k) = arg max
θ
[
I (D = k)
f subX(k)
Prθ (D = k)
]
.
The estimator θ̂c(k) was suggested by Koopmeiners et al. (2012). Overall, the MLEs derived
from (1) and (3), respectively, can be written as
θ̂ =
K∑
k=1
I(D = k)θ̂(k) and θ̂
c =
K∑
k=1
I(D = k)θ̂c(k).
For every observed pair
(
k,x (k)
)
, f subX(k) = fX(k) for all θ and, consequently,
θ̂fix(k) := arg maxθ
fX(k) = arg max
θ
f subX(k) = θ̂(k)
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and
θ̂fix =
K∑
k=1
I(D = k)θ̂fix(k) =
K∑
k=1
I(D = k)θ̂(k) = θ̂,
which means that MLEs stay unchanged for maximization of either L and Lfix.
2.2 Conditional and Unconditional Information
The superscript obs is used to denote the observed information (and quantities obtained
from it); and the superscript fix is used to denote the quantities derived assuming that study
stops at a pre-determined fixed sample size (no adaptation). As previously, the superscript
c denotes quantities obtained from the conditional likelihood (4) and the stopping stage is
referenced, when needed, in subscripts.
(0,0)
c1
c2
stopped
at stage 1
stopped
at stage 2
continued
to stage 3
Z 2
Z1
(a) Sketch of support components by
(scaleless) stage-specific test statistics
(0,0)
c1
c2
stopped
at stage 1
stopped
at stage 2
continued
to stage 3
Z (
2)
Z(1)
(b) Sketch of support components by
(scaleless) cumulative test statistics
Figure 1: Support associated with different stopping decisions when K = 3; ck is the
critical value for stopping at stage k.
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With this notation, the observed information measures derived from L (2), Lc(4), and
Lfix(5), respectively, are
Iobs(k) = −
∂2
∂θ2
log f subX(k)(x (k)|θ) = −
∂2
∂θ2
I(D = k) log fX(k)(x (k)|θ), (6)
Iobs,c(k) = Iobs(k) +
∂2
∂θ2
log Prθ (D = k) and (7)
Iobs,fix(k) = −
∂2
∂θ2
log fX(k) . (8)
Observed information matrices evaluated at MLEs are positive definite. Therefore,
∂2
∂θ2
log Prθ (D = k) |θ=θ̂ < 0 and Iobs,c(k) |θ=θ̂ < Iobs(k) |θ=θ̂.
Stopped expected information measures are
I(k) := EX(k)
[Iobs(k) ] = ∫ · · · ∫ Iobs(k) f subX(k)(x (k)|θ)Prθ(D = k)
n(k)∏
i=1
dxi and
Ic(k) := EX(k)
[
Iobs,c(k)
]
=
∫
· · ·
∫ [
Iobs(k) +
∂2
∂θ2
log Prθ (D = k)
] f subX(k)(x (k)|θ)
Prθ(D = k)
n(k)∏
i=1
dxi.
Under Prθ(D = k) ≡ 1, I(k) and Ic(k) reduce to Fisher information from n(k) observations:
Ifix(k) =
∫
· · ·
∫ [
− ∂
2
∂θ2
log fX(k)(x (k)|θ)
]
fX(k)(x (k)|θ)
n(k)∏
i=1
dxi. (9)
Overall, the expected (Fisher) information measures are
I = E [Iobs(D)] = ED [I(k)] = D∑
k=1
Prθ(D = k)EX(k)
[Iobs(k) ] and
Ic = E
[
Iobs,c(D)
]
= ED
[Ic(k)] = D∑
k=1
Prθ(D = k)EX(k)
[
Iobs,c(k)
]
= I − ED
[
− ∂
2
∂θ2
log Prθ (D)
]
. (10)
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Note that the information loss incurred by conditioning is equal to the amount of Fisher
information about θ in the early stopping rule, namely ED
[
− ∂2
∂θ2
log Prθ (D)
]
. If Prθ (D)
does not depend on θ, I = Ic. If the fact that Ifix(k) assumes Prθ(D = k) ≡ 1 is ignored,
the use of Ifix(k) with every D = k leads to
Ifix :=
K∑
k=1
Prθ (D = k) Ifix(k) .
Since f subX(k)(x (k)|θ) can be positive only when D = k, and f subX(k)(x (k)|θ) = fX(k)(x (k)|θ)
when D = k, I(k) is re-written as
I(k) =
∫
· · ·
∫
I(D=k)
[
− ∂
2
∂θ2
log fX(k)(x (k)|θ)
]
fX(k)(x (k)|θ)
Prθ(D = k)
n(k)∏
i=1
dxi, (11)
From (9) and (11), I(k) 6= Ifix(k) under GSDs. At θ = θ̂, ∂
2
∂θ2
log fX(k)
(
x (k)|θ = θ̂
)
≤ 0 and
I(k) ≤ Ifix(k) and I ≤ Ifix.
2.3 Example: Pocock One-Sided Two-Group Sequential Z-test
Pocock’s design is a simple two-stage study design for testing H0 : θ = 0 versus H1 : θ = θ1
with Xi ∼ N(θ, 1). Under n1 = n2 = 100,c1 = 2.18 is used to secure an overall type 1 error
rate α = 0.025 with a one sided z test. If Z1 ≤ 2.18, Z2 is also observed, where
Zk =
1√
nk
n(k)∑
i=n(k−1)+1
Xi =
√
nk · X¯k d= N(θ, 1).
If there is no possibility of interim stopping, Fisher information from both stages combined
is Ifix(2) = 200. This directly follows from the additivity property of Fisher information for
independent data.
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(c) θ̂, a mixture of θ̂(1) and θ̂(2)
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(f) θ̂c, a mixture of θ̂c(1) and θ̂
c
(2)
Figure 2: Histograms of MLEs for the Pocock example with critical value c1 = 2.18.
θ Measure θ̂(1) θ̂
c
(1) θ̂(2) θ̂
c
(2)
0.0 Bias 0.2524 -0.1865 -0.0017 0.0025
0.0 SD 0.0323 0.3136 0.0691 0.0741
0.0 MSE 0.0647 0.1331 0.0048 0.0055
2.18 Bias 0.0796 -0.1357 -0.0398 0.0056
2.18 SD 0.0599 0.2972 0.0584 0.0852
2.18 MSE 0.0099 0.1068 0.0050 0.0073
Table 1: Monte-Carlo Simulation study (100, 000 repetitions) for the two stage Pocock
design; n1 = n2 = 100.
12
−0.4 −0.2 0.0 0.2 0.4
−
2
−
1
0
1
2
3
(a) Study stops with stage 1. Z1 =
√
n1X¯1 ∈ {2.3(thin), 2.4, 2.5, 2.6(thick)}.
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(b) Study continues to stage 2. Z1 =
√
n1X¯1 ∈ {2.0(thin), 1.5, 1.0, 0.5(thick)}.
Figure 3: Log-likelihood plots as a functions of θ given selected realizations of Z1 =
√
n1X¯1;
n1 = n2 = 100, X ∼ N(θ, 1); dotted lines trace maximums. The critical value for stopping
is c1 = 2.18.
Figure 2 shows histograms of θ̂(1), θ̂
c
(1), θ̂(2), and θ̂
c
(2) estimated from 100, 000 Monte-Carlo
samples assuming θ = 2.18. Table 1 reports Monte-Carlo biases, standard deviations (SD),
and mean squared errors (MSE) under θ = 0 and under θ = 2.18. In this example, the study
is stopped for efficacy at stage 1 if Z1 > 2.18 and proceeds to stage 2 when Z1 ≤ 2.18. If the
study is stopped at stage 1, the support for X¯1 starts at 2.18
√
100 = 0.218 and stretches
to +∞. If the study continues through stage 2, support for X¯1 ranges from −∞ to 0.218.
However, it is still possible to obtain a conditional MLE outside the range of support, that
is, above or below 0.218 at stage 1. Figure 3 shows that conditional likelihoods do not
allow accurate estimation of θ when observed Z1 is close to the critical value for deciding
to stop, and the conditional MLEs start diverging to ±∞.
In GSDs, the “information fraction” is used to justify times or sample sizes of interim
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(a) Information Measures from the Con-
ditional Density: Ic(1) and Ic(2) (solid),
Ifix(1) and Ifix(2) (dotted), I(1) and I(2)
(dashed); thick right is for stopping at
stage 1 and a thick left for stage 2.
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(b) Information Measures from the Un-
conditional Density: Ic (solid), Ifix (dot-
ted), I (dashed).
Figure 4: Information Measures as a Function of θ
analyses. In two-stage designs, the information fraction is often estimated as Ifix(1) /Ifix(2) ,
which in the Pocock example is equal to 1/2 since Ifix(1) = 100 and Ifix(2) = 200. This
information fraction argument silently assumes that study stops at a pre-determined sample
size. In Figure 4, Ifix(1) and Ifix(2) are plotted as a function of θ with dotted horizontal lines.
Figure 4 also graphs information in conditional and unconditional likelihoods.
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3 New Group Sequential Designs Relying on Mixture
Distributions
Even though the normality does not hold when there is a possibility of early stopping,
the critical values for controlling type 1 error are correctly calculated. With the use of
Monte-Carlo methods, data generated from stage-specific normal distributions with GSD-
determined early stopping inherently generate draws from correct mixtures. Similarly,
numeric integration [see Jennison and Turnbull (1999)] also correctly estimates type error
and power by the use of the recursive sub-density formula of Armitage et al. (1969).
Currently, the design of many group sequential trials starts with choosing an α-spending
function. Then, “Information fraction” considerations are used to define times or sample
sizes of interim analyses that secure the overall power at a desired level. Statistical power to
detect one or another treatment effect is only described. It is important to note that stage-
specific sample sizes in such study designs are not driven by desired stage-specific power
requirements, but fully determined by a (1) chosen spending functions, (2) “information
fraction” for interim looks, and (3) a “maximum information” to reach a desired overall
power.
In contrast, this manuscript proposes GSDs driven by a sequence of ordered alternative
hypotheses attainable with a predetermined statistical power while controlling type 1 error.
3.1 New GSDs Determined by Ordered Alternatives
Consider a study design in which stage-specific sample sizes {nk} and and critical values
{ck} are determined by an α-spending function and at least 1 − β power of rejecting
H0 : θ = 0 for each alternative hypothesis HAk : θ = θk, where θ1 > θ2 > · · · > θK > 0.
15
Feature Mathematical Definition
overall type 1 error α =
∑K
k=1 αk
∏k−1
j=1 (1− αj)
stage-specific type 1 error αk = Prθ
(
Z(k) > ck
∣∣ ∩k−1j=1 {Z(j) ≤ cj} , θ = 0)
α-spending function α(k) =
∑k
j=1 αj
∏j−1
i=1 (1− αi)
overall power 1− β(θ) = ∑Kk=1[1− βk(θ)]∏k−1j=1 [βj(θ)]
stage-specific power 1− βk(θ) = Prθ
(
Z(k) > ck
∣∣ ∩k−1j=1 {Z(j) ≤ cj} , θ)
cumulative power 1− β(k) (θ) =
∑k
j=1[1− βj(θ)]
∏j−1
i=1 [βi(θ)]
overall type 2 error β(θ)
stage-specific type 2 error βk(θ)
β-spending function β(k) (θ)
stage-specific rejection region Rk =
{
Z(k) > ck
} ∩ {∩k−1j=1 {Z(j) ≤ cj}}
stage-specific rejection probability Prθ (Rk|θ)
Table 2: Definitions of GSD operational characteristics (k = 1, . . . , K);
∏0
i=1[·] = 1.
Specifically, {nk} and {ck} are identified recursively to satisfy α(k) ≤ α and under θ = θk,
1− β(k)(θk) = 1− β. The first stage critical value c1 and sample size n1 are determined by
α1 and by β = β1 which depends on the first stage alternative hypothesis θ1. If the same
alternative and sample size were used for stage 2, the power at stage 2 would be greater
than 1− β. A smaller θ2 < θ1 and α2 are chosen to define a stage 2 sample size n2 and the
critical value c2 that will keep the power at 1 − β. Additional decreasing hypotheses and
αk are used to determine samples sizes and critical values for following stages. Thus, this
design is “flexible”. The total number of stages, K, does not need to be pre-determined.
However, for ease of illustration, henceforth a fixed K is considered.
The use of both α− and β− spending functions was suggested by Pampallona et al.
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(2001) for use with a single alternative hypothesis at predetermined samples sizes. But
the use of a sequence of ordered alternative hypotheses with the same power to determine
sample sizes is new. In this optimization problem, there are K + 1 (marginal) restrictions
(type 1 error = α under H0 and power = 1 − β under each alternative) and 2Kunknown
quantities {n1, . . . , nK , c1, . . . , cK}. The Z(k) pivots do not have to be normal random
variables. More details are given through the example that follows.
3.2 One Simple Option
It is common to select an α-spending function that determines conditional type 1 errors
while keeping the overall type 1 error equal to α. For simplicity of exposition, for all k,
assume that αk = α0 leading to
α =
K∑
k=1
α0
k−1∏
j=1
(1− α0) = α0
K∑
k=1
(1− α0)k−1 = α0
(
1− (1− α0)K
)
, (12)
where the last equality follows from a property of geometric sequences. Thus, for a fixed
K, stage-specific critical values are defined via (12). For a two-stage design with α = 0.05,
α0 ≈ 0.0257; at K = 3, α0 ≈ 0.0172; at K = 4, α0 ≈ 0.0144.
The numerical example that follows shows how stage-specific power requirements can
be determined from the overall power 1−β at θ = θk requirement and sample sample sizes
can be found that satisfy these requirements.
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3.2.1 A numeric example at K = 3.
Consider HA1 : θ = 0.3, HA2 : θ = 0.2, and HA3 : θ = 0.1. Stage-specific nk and ck
(k = 1, 2, 3) are found from the following system of (nonlinear) equations:
Prθ
(
Z(1) > c1
∣∣θ = 0) = α0
Prθ
(
Z(2) > c2
∣∣Z(1) ≤ c1, θ = 0) = α0
Prθ
(
Z(3) > c3
∣∣Z(2) ≤ c2, Z(1) ≤ c1, θ = 0) = α0
Prθ
(
Z(1) > c1
∣∣θ = 0.3) = 1− β
Prθ
(
Z(1) > c1
∣∣θ = 0.2)+ Prθ ({Z(2) > c2} ∩ {Z(1) ≤ c1} |θ = 0.2) = 1− β
3∑
k=1
Prθ
({
Z(k) > ck
} ∩ {∩1≤j≤k−1 {Z(j) ≤ cj}} ∣∣θ = 0.1) = 1− β (13)
Recall that Z(1), Z(2) and Z(3) depend on the first n1, n1+n2, and n1+n2+n3 observations,
respectively. Resolving (13) numerically, under X ∼ N(θ, 1) and α0 ≈ 0.0172, one finds
n1 = 98 and c1 = 2.12 for stage 1, n2 = 98 and c2 = 2.01 for stage 2, and n3 = 576 and
c3 = 2.02 for stage 3. Using these stage-specific sample sizes and critical values, Table
3 reports operational characteristics of the new GSD based on a Monte-Carlo resampling
with 100, 000 iterations.
θ Prθ (R1|θ) Prθ (R2|θ) Prθ (R3|θ) E[N |θ]
0.0 0.0170 0.0336 0.0509 751
0.1 0.1287 0.3044 0.7983 584
0.2 0.4424 0.8016 0.9998 267
0.3 0.8018 0.9877 1.0000 125
Table 3: Stage-specific probabilities of rejecting H0. E[N |θ] is the average sample size.
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As it will be shown in Section 3.3, if each Z(k) is a continuous function of a monotone
likelihood ratio, then the proposed test is the most powerful against any ordered alternatives
θ1 > θ2 > · · · > θK > 0 given an α-spending function.
3.3 Most Powerful Group Sequential Tests for Ordered Alterna-
tives
Let X ∼ fX(θ), where f belongs to the exponential family. Without a possibility of
early stopping, the likelihood for a realization x = (x1, . . . , xn) of a random sample X =
(X1, . . . , Xn) is
L (θ|x ) =
n∏
i=1
fX (x ) = h (x ) g (T (x ) |θ) = h (x ) eη(θ)T (x )+A(θ)
where all relevant information about θ is absorbed by a sufficient statistic T (x ). Assume
the test statistic Z is a one-to-one transformation of T .
If LR(t) := g(t|θ)/g(t|θ0) is a monotone likelihood ratio (MLR) in t, then the Karlin-
Rubin theorem allows the construction of uniformly most powerful tests. Using the notation
in Section 2,
Lc (θ|k,x (k)) := I (D = k)
Prθ (D = k)
h
(
x (k)
)
eη(θ)T(x (k))+A(θ)
= I (D = k)h
(
x (k)
)
eη(θ)T(x (k))+A(θ)+log Prθ(D=k), (14)
L (θ|k,x (k)) := I (D = k)h (x (k)) eη(θ)T(x (k))+A(θ), (15)
with associated likelihood ratios:
LRc(t) :=
Lc (θ|k,x (k))
Lc (θ0|k,x (k)) and LR(t) := L
(
θ|k,x (k)
)
L (θ0|k,x (k)) .
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For every D = k, LRc(t) = LR(t) = exp
[
(η(θ)− η(θ0))T(k) + (A(θ)− A(θ0))
]
which
means that the MLR property is preserved with early stopping.
Theorem 1 For any fixed (α1, . . . , αK) and (n1, . . . , nK) (1) {T(k) > ck} is a UMP αk-level
test and (2) no test is more powerful than {T(D) > cD}.
Proof. (1) As shown above, conditional on D = k, T(k) is sufficient in exponential families
and the MLR property is preserved. By the Karlin-Rubin theorem, the test based on T(k),
is uniformly most powerful.
(2) Using Table 2 notation,
1− β(θ) =
K∑
k=1
(
k−1∏
j=1
[βj(θ)]
)
[1− βk(θ)] = 1−
K∏
k=1
βk(θ).
At K = 1, α1 and n1 uniquely define c1 and
{
T(1) > c1
}
is a UPM by part 1 with a stage-
specific power curve 1 − β1(θ). At an arbitrary K, αk and nk uniquely define ck and, by
part 1 of the theorem, the stage-specific power 1− βk(θ), is the highest. Consequently, for
any choice of D, the power of the test
{
T(D) > cD
}
is 1 − β(θ) = 1 −∏Kk=1 βk(θ). This
power is the highest, because the stage specific type 2 errors βk(θ) are the lowest for each
k at any θ. Q.E.D.
Even if Tk is normal, the distributions of T(k) are not normal, but Armitage’s recur-
sive sub-density formula can be used to evaluate the distribution of T(k). For example,
at K = 2, the sub-density of T(2) is f
sub
T(2)
(t|θ) = ∫ c1−∞ fT(2)|T(1)(t|t1, θ)fT(1)(t1|θ)dt1 and its
density is fT(2)(t|θ) = f subT(2)(t|θ)
(∫ c1
−∞ fT(1)(t1|θ)dt1
)−1
. Recursively, the density conditional
on reaching the kth interim analysis is
fT(k)(t|θ) =
∫ ck−1
−∞ fT(k)|T(k−1)(t|tk−1, θ)fT(k−1)(tk−1|θ)dtk−1∫ ck−1
−∞ fT(k−1)(tk−1|θ)dtk−1
.
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This section has shown the impact of the possibility of early stopping on the finite
sample distribution of test statistics. Section 4 shows how interim decisions to stop or
continue affect asymptotic properties.
4 Large Sample Properties of Parameter Estimates
Because unconditional MLEs (θ̂) retain more information and have smaller MSEs than
conditional MLEs (θ̂c), henceforth only unconditional MLEs are considered and they are
now referred to simply as MLEs. To describe local asymptotic characteristics, the approach
considered for sample size recalculation in Tarima and Flournoy (2019) is adopted. Let
f(x|θ, η) depend on a parameter of interest, θ, and a nuisance parameter, η. The objective
is to test a null H0 : θ = 0 versus local alternatives HAk : θ = hk/
√
n1. The kth stage-
specific estimates (θ̂k, η̂k) of (θ, η) and their statistical models are called regular if, without
the possibility of early stopping,
√
nk
 θ̂k − θ
η̂k − η
 d→ N
 0
0
 ,
 σθθ σθη
σθη σηη
 , (16)
where the limiting covariance matrix is positive definite with finite elements. Then,
ξk :=
√
nk
(
θ̂k − θ
)
σ−1θ
d→ N (0, 1) , k = 1, . . . , K, (17)
where σ2θ := σθθ. Assumption (16) was described in Tarima and Flournoy (2019) to encom-
pass specific assumptions for
• independent, identically distributed observations by Crame´r [e.g., for example, Fer-
guson (1996)],
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• independent not identically distributed observations [e.g., Philippou et al. (1973)],
• dependent observations [e.g., Crowder (1976)],
• and densities whose support depends on parameters [e.g., Wang et al. (2014)].
All these specific sets of assumptions include assumptions of the existence and consistency
of the MLE.
4.1 Asymptotic Results under Local Alternatives for Two-Stage
Group Sequential Designs
With large sample sizes, due to (16), MLEs calculated on n1+n2 independent and identically
distributed observations can be approximated using
θ˜(2) =
n1
n1 + n2
θ̂1 +
n2
n1 + n2
θ̂2 + op
(
n−0.51
)
if data collection did not stop at stage 1, otherwise use θ˜(1) = θ̂1. Then, with a random
stopping index D,
θ˜(D) = I(D = 1)θ˜(1) + I(D = 2)θ˜(2).
As shown in Theorem 1 in Tarima and Flournoy (2019), the asymptotic properties of
the standardized estimate
V(D) :=
√
n(D
(
θ˜(D) − θ
)
/σθ
= I(D = 1)
√
n1
(
θ˜(1) − θ
)
/σθ + I(D = 2)
√
n1 + n2
(
θ˜(2) − θ
)
/σθ (18)
depend on the existence and distribution of the limiting random variable r(D) that is defined
by
I(D = 1) + I(D = 2)
n1 + n2
n2
d→ r(D),
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as n1 →∞. Then, for a sequence of local alternative hypotheses θ = h/√n1,
Prθ
(
V(D) < v
) → p1Φ (v|D = 1)
+ (1− p1)
∫ c1
−∞
Φ
(√
r(D)v −
√
r(D) − 1y
)
φ (y|D = 2) dy, (19)
where p1 = limn1→∞ Prθ (D = 1) is the limiting stage 1 stopping probability. Using previous
terminology, under θ = 0, V(2) = Z1 = Z(1) if stopped at stage 1, and V(2) = Z(2), if the
study proceeds to the second stage.
4.2 Example: The Two-Stage One-Sided Pocock Design
If n1 = n2, then r(D) = 1 + I(D = 2) and V(D) = I(D = 1)Z1 + I(D = 2) (Z1 + Z2) /
√
2.
Then,
Prθ
(
V(D) < v
)→ (α/2)Φ (v|Z1 > c1) + (1− α/2)∫ c1
−∞
Φ
(√
2v − y
) φ (y)
Pr (y ≤ c1)dy.
Note if Z1 ≤ c1, then
Prθ
(
Z1 + Z2√
2
< v|Z1 ≤ c1
)
=
∫ c1
−∞
Φ
(√
2v − y
) φ (y)
Pr (y ≤ c1)dy,
which is a continuous mixture of distributions.
4.3 Asymptotic Results under Local Alternatives for K-Group
Sequential Designs
With large samples, the MLE given D = k can be approximated recursively by
θ˜(k) ≈
n(k−1)
n(k)
θ˜(k−1) +
nk
n(k)
θ̂k ≈
k∑
j=1
nj
n(k)
θ̂j, (20)
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where θ˜(k−1) is an MLE based on cumulative data from stages 1 to k−1, and θ̂k is the MLE
based on stage k data only. In K-stage GSDs, the limiting random variable r(D) generalizes
to
K∑
k=1
I(D = k)
n(k)
nk
d→
K∑
k=1
I(D = k)r(k) := r(D), (21)
where r(k) is the asymptotic ratio of a cumulative and a stage-specific sample size. Equation
(21) generalizes a 2-dimensional definition of r(D). Thus, r(D) is a multinomial random
variable with support on r(k), k = 1, . . . , K.
Let n(k)/nj → r(k)j ∈ (0,∞), j ≤ k with r(k)k = r(k), then equations (20) and (21) lead
to the standardized test statistic given on D = k:
V(k) =
√
n(k)
k∑
j=1
nj
n(k)
(
θ̂j − θ
)
=
k∑
j=1
√
nj
n(k)
√
nj
(
θ̂j − θ
)
→
k∑
j=1
ξj√
r(k)j
.
Hence, the distribution of V(D) is
Prθ
(
V(D) < v
) → K∑
k=1
Prθ
(
r(D) = r(k)
)
Prθ
(
k∑
j=1
ξj√
r(k)j
< v
∣∣∣r(D) = r(k)) . (22)
5 Example
To illustrate use of a sequence of ordered alternative hypotheses in designing a group
sequential study, a dataset of 7, 874 persons available in Dr. Terry Therneau’s “Survival”
R package is reanalyzed. Serum free light chain (FLC), age, sex, creatinine, survival status
and a follow-up period are available in this dataset. This smaller dataset is a subset of a
larger dataset of 15, 759 persons where relationship between FLC and survival was analyzed
using a proportional hazards model [Dispenzieri et al. (2012)].
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A Cox proportional hazards regression model is used to analyze the effect of FLC on
survival hazards controlling for age, sex and creatinine:
log h(t|FLC,A,M,C) = log hb(t) + β1FLC + β2A+ β2M + β3C,
where hb(t) is the baseline survival hazard; A is “Age”; M is an indicator of male sex,
and C is a creatinine value. When this model is applied to the whole 7, 874 patients,
the regression coefficient of FLC (β1) is estimated as β̂1 = 0.1368 (SE = 0.0093) with
p < 0.0001. Obviously, this large sample size was not needed to prove the significance of
association.
Consider a three stage sequential design simulated in Table 3 for detecting ordered
standardized effect sizes 0.3, 0.2, and 0.1 with 80% power each while controlling overall
overall type I error at 5%. Per this design, Z-values need to be compared against the
critical values of 2.12 (stage 1, n1 = 98), 2.01 (stage 2, n2 = 98), and 2.02 (stage 3,
n = 576). At stage 1, β̂1 = 0.1526 (SE = 0.0520) with p = 0.0033. The Z-statistic is
2.9379 > c1 = 2.12. The study is stopped at stage 1 and the hypothesis of no association
is rejected.
To convert this example into a simulation study, this three-stage GSD is repeated 1, 000
times on the randomly reshuffled FLC dataset. Overall the rejection rate was 74% with
the average sample size of 399. Study stopped at stage 1 in 35% simulations and at stage
2 in 24%.
6 Summary
This paper focuses on GSDs with stopping rules dependent on a parameter of interest.
The information in conditional MLEs and unconditional MLEs is derived in Section 2, and
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the loss using conditional MLEs is found to be I − Ic = −ED
[
∂2
∂θ2
log Prθ (D = k)
]
≥ 0.
These findings show that “information fraction” should not be calculated using the amount
of information in a sample with a fixed sample size Ifix(k) . With normal random variables,
Ifix(k) /Ifix(K) = n(k)/n(K) . The correct “information fraction” is I(k)/I(K), the use of which
requires substantial computational effort. This difficulty is avoided with the use of the
new GSD that is presented in Section 3. The new GSD ensures the desired power (for
example, 80%) if data came from any of the multiple ordered alternative hypotheses at a
pre-determined overall type I error (for example, 5%). Since clinical research community
understands statistical power, this new approach will likely be easily adopted by clinicians.
The traditional assumption of multivariate normality does not hold in the presence
of random stopping rules. Distributions of sufficient statistics T(k) that are normally dis-
tributed without possibility of early stopping become non-normal in GSDs. Consequently,
information measures and information fractions are changed as well. Despite their non-
normality, nevertheless, T(k) continues to be sufficient and if monotone likelihood ratio
holds without adaptation, it continues to hold with adaptation. This immediately leads to
most powerful tests at a predefined α-spending function. It is important to note that each
choice of an α−spending function “cuts out” a different subspace of the sample space with
its own sub-σ-field and probability measure on this “cut-out” measurable space. This is
why Theorem 1 conditions on a pre-determined α-spending function.
Section 4 reports local asymptotic properties of the MLEs presented in Sections 2 and
3. The distributions of GSD’s MLEs are different from regular non-GSD MLEs. Their
asymptotics, under regularity conditions, is described by mixtures and truncated normal
random variables. Finally, Section 5 illustrates how this approach applies to GSD in Cox
proportional hazards regression models.
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Overall, researchers need to be careful dealing with information fractions when designing
sequential trials and sequential designs powered for multiple ordered alternative hypotheses
is recommended.
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